Individual SAMe-TT2R2 variables and other risk factors in relation with PINRR < 65%
| . | OR (95% CI) . | P-value . |
|---|---|---|
| Female sex | 1.48 (1.12–1.96) | 0.006 |
| Age < 60 years | 1.38 (0.93–2.04) | 0.11 |
| More than two medical comorbidities | 2.19 (1.61–2.98) | <0.0001 |
| Treatment interaction (e.g. Amiodarone) | 1.48 (0.98–2.24) | 0.06 |
| Tobacco | 1.17 (0.92–1.50) | 0.21 |
| Alcohol abuse | 3.08 (1.73–5.48) | <0.0001 |
| eGFR < 30 mL/min/1.73 m2 | 1.49 (1.11–2.01) | 0.008 |
| History of malignancy | 1.93 (1.29–2.91) | 0.002 |
| Diabetes mellitus | 1.56 (1.13–2.16) | 0.007 |
| Heart failure or LVEF < 40% | 1.66 (1.27–2.20) | <0.0001 |
| Liver disease | 1.61 (0.31–8.38) | 0.57 |
| . | OR (95% CI) . | P-value . |
|---|---|---|
| Female sex | 1.48 (1.12–1.96) | 0.006 |
| Age < 60 years | 1.38 (0.93–2.04) | 0.11 |
| More than two medical comorbidities | 2.19 (1.61–2.98) | <0.0001 |
| Treatment interaction (e.g. Amiodarone) | 1.48 (0.98–2.24) | 0.06 |
| Tobacco | 1.17 (0.92–1.50) | 0.21 |
| Alcohol abuse | 3.08 (1.73–5.48) | <0.0001 |
| eGFR < 30 mL/min/1.73 m2 | 1.49 (1.11–2.01) | 0.008 |
| History of malignancy | 1.93 (1.29–2.91) | 0.002 |
| Diabetes mellitus | 1.56 (1.13–2.16) | 0.007 |
| Heart failure or LVEF < 40% | 1.66 (1.27–2.20) | <0.0001 |
| Liver disease | 1.61 (0.31–8.38) | 0.57 |
CI, confidence interval; eGFR, estimated glomerular filtration rate; OR, odds ratio; INR, international normalized ratio; LVEF, left ventricular ejection fraction; PINRR, percentage of INRs in therapeutic range.
Individual SAMe-TT2R2 variables and other risk factors in relation with PINRR < 65%
| . | OR (95% CI) . | P-value . |
|---|---|---|
| Female sex | 1.48 (1.12–1.96) | 0.006 |
| Age < 60 years | 1.38 (0.93–2.04) | 0.11 |
| More than two medical comorbidities | 2.19 (1.61–2.98) | <0.0001 |
| Treatment interaction (e.g. Amiodarone) | 1.48 (0.98–2.24) | 0.06 |
| Tobacco | 1.17 (0.92–1.50) | 0.21 |
| Alcohol abuse | 3.08 (1.73–5.48) | <0.0001 |
| eGFR < 30 mL/min/1.73 m2 | 1.49 (1.11–2.01) | 0.008 |
| History of malignancy | 1.93 (1.29–2.91) | 0.002 |
| Diabetes mellitus | 1.56 (1.13–2.16) | 0.007 |
| Heart failure or LVEF < 40% | 1.66 (1.27–2.20) | <0.0001 |
| Liver disease | 1.61 (0.31–8.38) | 0.57 |
| . | OR (95% CI) . | P-value . |
|---|---|---|
| Female sex | 1.48 (1.12–1.96) | 0.006 |
| Age < 60 years | 1.38 (0.93–2.04) | 0.11 |
| More than two medical comorbidities | 2.19 (1.61–2.98) | <0.0001 |
| Treatment interaction (e.g. Amiodarone) | 1.48 (0.98–2.24) | 0.06 |
| Tobacco | 1.17 (0.92–1.50) | 0.21 |
| Alcohol abuse | 3.08 (1.73–5.48) | <0.0001 |
| eGFR < 30 mL/min/1.73 m2 | 1.49 (1.11–2.01) | 0.008 |
| History of malignancy | 1.93 (1.29–2.91) | 0.002 |
| Diabetes mellitus | 1.56 (1.13–2.16) | 0.007 |
| Heart failure or LVEF < 40% | 1.66 (1.27–2.20) | <0.0001 |
| Liver disease | 1.61 (0.31–8.38) | 0.57 |
CI, confidence interval; eGFR, estimated glomerular filtration rate; OR, odds ratio; INR, international normalized ratio; LVEF, left ventricular ejection fraction; PINRR, percentage of INRs in therapeutic range.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
